The effect of serum IGF-1, IGFBP-3 and erythrocyte transfusions on development of mild retinopathy of prematurity

Serum IGF-1, IGFBP-3 düzeylerinin ve eritrosit transfüzyonunun prematüre retinopatisi üzerinde etkisi

Davut Bozkaya, Ebru Ergenekon, Ayşegul Yücel, Şengül Özdek, İbrahim Hırıfanoğlu, Özden Turan, Canan Turkyılmaz, Esra Önal, Esin Koç, Yıldız Atalay

1Department of Pediatrics, Gazi University Hospital, Ankara, Turkey
2Division of Newborn Medicine, Department of Pediatrics, Gazi University Hospital, Ankara, Turkey
3Department of Immunology, Gazi University Hospital, Ankara, Turkey
4Department of Opthtalmology, Gazi University Hospital, Ankara, Turkey

Abstract

Introduction: Most important factors in retinopathy of prematurity (ROP) are prematurity and oxygen toxicity although blood transfusions, insulin like growth factor-1 (IGF-1), insulin like growth factor binding protein 3 (IGFBP-3) and vascular endothelial growth factor (VEGF) also have important roles. The objectives of this study were, to measure IGF-1 and IGFBP-3 levels in preterm newborns before and after blood transfusion and assess if the effect of transfusion in development of ROP is via these mediators, and to investigate whether IGF-1 and IGFBP-3 levels measured at 32 and 33 gestational age (GA) were different in preterm newborns with and without ROP.

Methods: Preterm newborns with gestational age ≤34 weeks were included and blood samples were obtained before and after red blood cell (RBC) transfusion.

Results: Thirty newborns were included, 17 of whom had ROP (stage 1: n=11, stage 2: n=5, stage 3: n=1). IGF-1 and IGFBP-3 levels did not change after RBC transfusion. Excluding the patient with stage 3 ROP all ROP patients were referred as mild ROP. No difference was observed between IGF-1 and IGFBP-3 levels of the patients with and without mild ROP. Patients with mild ROP had significantly more number of transfusions.

Discussion and Conclusion: Erythrocyte transfusion increased the frequency of ROP, whereas IGFBP-3 and IGF-1 were not associated of ROP.

Keywords: Retinopathy of prematurity; IGF-1; IGFBP-3; transfusion.
Retinopathy of prematurity (ROP) is one of the leading causes of blindness in children. Despite controlled use of oxygen the disease still continues to be a problem in babies <1000 birth weight particularly <750 g in the developed world possibly due to the increased survival of extremely low birth weight infants (ELBW).\[1–3\] It is even more frequent in the developing world in relatively larger newborns with birth weight 1500 g or above. This finding is thought to be due to especially controlled neonatal intensive care conditions particularly oxygen and transfusions in developing countries resulting in increased survival together with also increased morbidity.\[3,4\]

Currently, prematurity, oxygen toxicity and many other factors are also believed to be effective in the development of ROP including initially low insulin like growth factor-1 (IGF-1) levels, high retinal vascular endothelial growth factor (VEGF) levels, blood transfusions, hyperglycemia, hypercarbia, clustered hypoxic events, sepsis and finally genetic factors.\[4–7\] However, there is no study to investigate the IGF-1 and IGFBP-3 association with erythrocyte transfusion.

Recent research suggests that there are 2 phases of ROP during which completely different management is required.\[8–12\] Phase 1 of ROP is the time right after birth when the preterm is born to an oxygen rich environment resulting in a sudden decrease in VEGF levels in retina. Since VEGF is a hypoxia induced mediator, hypoxia results in_P onpressed VEGF production. This is also a time when a sudden drop in IGF-1 levels occurs which normally come readily from placenta and amniotic fluid when the fetus is in the uterus. VEGF is known as an angiogenetic mediator which also is important in retinal vascularization. IGF-1 which is actually a growth factor has been shown to act as a permissive factor in angiogenetic effects of VEGF. Therefore when VEGF and IGF-1 levels fall after preterm birth retinal vascularization arrests temporarily although retinal cell metabolism and growth continues which later on result in relative tissue hypoxia and subsequent retinal VEGF stimulation. Then starts the phase 2 of ROP during which both the increase in retinal VEGF and serum IGF-1 work together for retinal neovascularization causing ROP. Therefore during phase 1 the hypoxic suppression of VEGF needs to be avoided together with the decrease in IGF-1 levels whereas in phase 2 both VEGF and IGF-1 effects need to be neutralized. 8–12 However there are other factors which are also effective in the development of ROP during these 2 phases. Blood transfusions have long been held responsible for ROP although the mechanism has not been clear. The iron load, free radicals and even the IGF-1 levels in packed red blood cells (PRBC) have been proposed as possible explanations for the effect of PRBCs on development of ROP.\[13–16\] In one study the insulin like growth factor binding protein 3 (IGFBP-3) has been shown to avoid proliferative ROP.\[17,18\] IGFBP-3 is the major binding protein for IGF-1 in the postnatal period and extends half life of IGF-1 from 30 minutes to 12–15 hours in the body.\[17,18\]

Objectives

To measure IGF-1 and IGFBP-3 levels in preterm newborns at risk for ROP before and after PRBC transfusion thereby to assess if the effect of PRBCs in development of ROP is via these mediators.

Materials and Method

This study was prospectively conducted to Gazi University Faculty of Medicine Neonatal Intensive Care Unit between January 2005 and June 2007. Ethical approval was obtained from the Ethics Committee of Gazi University Faculty of Medicine, Ankara Turkey. The study adheres to the Declaration of Helsinki. Informed written consents were obtained from the families of newborns planned to be included in the study. The erythrocyte transfusion of the babies was performed according to the liberal transfusion procedure of the IOWA study.\[19\]

Infants with 24th–34th of GA who underwent blood transfusions on the first 3 days of life and examined of ROP were included.

We excluded the newborns with gestational age >34 weeks, hemodynamic significant PDA and higher stage (stage 3 and 4) intracranial hemorrhage and not examined of ROP.

Blood samples of 1 ml were collected for IGF-1 and IGFBP-3 assays before and 30 minutes after PRBC transfusion. Serum samples were taken from at least 2 transfusions from all patients. The first sample was taken after the 3rd day of life. Serum was separated by 3500 rpm centrifugation for 5 minutes and kept at -80°C till the time of measurement. PRBC transfusions were given based on the following criteria as well as the attending neonatologist’s judgement;

- Transfuse if on the ventilator or severe heart disease with Hb <15 g
- Transfuse if on nasal CPAP with increased oxygen requirement with Hb <10 g
- Transfuse if on room air with Hb <7 g with symptoms which could be attributed to anemia

Irradiated and filtered PRBCs were given as 15 ml/kg over 3 hours.

IGF-1 Measurements: IGF-1 levels were measured by using commercial ELISA kit (Biosource Human IGF-1 Cytelisa, Biosource, Rue de l’Industrie 8, B-1400 Nivelles sensitivity: 4.9 ng/ml) according to the manufacturer’s instructions. First 50 µl serum was mixed with extraction solution and centrifuged at 12000 rpm for 2 minutes. 100 µl supernatant was taken and after neutralization 25 µl of solution was added to ELISA plate to be mixed with 100 µl antiIGF-1 antibody for 90 minutes. After washing with the automatic ELISA washer for 3 times chromogen substrate was added to the plate. After 30 minutes the reaction was stopped with stop solution and the plates were read spectrophotometrically at 405 nm wavelength. The optical density (OD) values were assessed with the Microsta statistical program and by using the OD of standard solutions with known IGF-1 levels the IGF-1 concentrations of the samples were calculated.

IGFBP-3 Measurements: IGFBP-3 levels were measured by using commercial ELISA kit (Biosource Human IGFBP-3 Cytelisa,
Biosource, Rue de l’Industrie 8, B-1400 Nivelles sensitivity: 10.5 ng/ml) according to the manufacturer’s instructions. 100 µl of serum and 100 µl of antiIGFBP-3 antibody were added on the ELISA plate. After 90 minutes at room temperature the plate was washed 3 times with automatic ELISA washer and chromogen substrate was added. The reaction was stopped 30 minutes later with stop solution and the plates were read spectrophotometrically at 405 nm wavelength. The optical density (OD) values were assessed with the Microsta statistical program and by using the OD of standard solutions with known IGFBP-3 levels the IGFBP-3 concentrations of the samples were calculated.

ROP Examinations: Newborns less than 32 weeks gestation or 1500 g birth weight or preterm newborns larger than 32 weeks but at risk for developing ROP for having had oxygen requirements or ventilatory support were examined by the ophthalmologist according to the American Academy of Pediatrics policy statement by indirect ophthalmoscopy. Before examination pupils were dilated with half strength 1.25% phenylephrine and 5% cyclopine and sedation with midazolam was given to the baby to avoid discomfort. ROP classification was made by the international classification of ROP according to the following criteria:

Stage 1: Demarcation line
Stage 2: Ridge formation
Stage 3: Fibrovascular proliferation from the ridge towards vitreous.
Stage 4: Partial retinal detachment
Stage 5: Total retinal detachment
Plus disease: Simply the increased tortuosity of the vessels.

Patients were continuously monitored by pulse oximetry during their intensive care stay and oxygen saturation measured by pulse oximetry was aimed to be kept between 88–92% to avoid oxygen toxicity.

Statistics
SPSS for windows 11.5 version was used for statistical analysis. Wilcoxon signed rank test was used to assess the difference between mediator levels before and after transfusion. Mann Whitney U test was used to assess the difference between GA, oxygen treatment duration, mediator levels and number of transfusions in the newborns with and without ROP. Backward logistic regression analysis was performed to assess the effects of the factors on ROP separately. The results are expressed as mean±SD unless stated otherwise and p<0.05 is accepted significant.

Results
Thirty newborns were included in the study; 9 female (30%), 21 male (70%), GA: 29.82±2.52 weeks range (26–34), BW: 1236±428.12 g range (613–2400), PRBC transfusions were given 4±3 range (1–13) times, the duration of mechanical ventilation: 6.5±7.8 days range (0–28), duration of oxygen therapy: 29.9±30.3 days range (0–109). ROP was diagnosed in 17 of the 30 patients (56.7 %); 11 with stage 1 ROP (64.7 % of total ROP), 5 with stage 2 ROP (29.4 % of total ROP) and 1 with stage 3 ROP (5.9 % of total ROP) was identified. For the ease of discussion the patients with stage 1 and 2 ROP are referred as mild ROP and 1 patient with stage 3 ROP was excluded from statistical analysis. First blood sampling for IGF-1 and IGFBP-3 levels were obtained on day 12.86±10.49 of life (Postconceptional age: 32 w) on all patients. Second sampling was obtained from 16 patients on the 18.5±10.48 days of life (Postconceptional age: 33 w).

Demographic and clinical data of the patients with and without ROP are presented in Table 1 and Figure 1. The patients with ROP had significantly lower GA, longer duration of ventilation and oxygen treatment, more episodes of infection, and more number of PRBC transfusions compared to the non-ROP group.

No statistically significant difference was found between pre-transfusion and postransfusion IGF-1 and IGFBP-3 levels in either of the 2 transfusion episodes when all patients were analyzed together.

No statistically significant difference was found between the mediator levels of patients with and without ROP (Table 2), however statistics were made only for the 1st transfusion episode due to the limited number of samples during the 2nd transfusion from the patients without ROP. The mediator values of the ROP (+) patients were not statistically different before and after PRBC transfusions.

The results were also analyzed between stage 1 ROP and stage 2 ROP patients to be able to find whether stage 2 ROP patients had significantly different clinical or laboratory findings than the stage 1 ROP patients. Patients with stage 2 ROP had smaller GA, longer duration of ventilation and oxygen, more

<table>
<thead>
<tr>
<th>Table 1. Demographic and clinical data of patients with and without mild ROP</th>
</tr>
</thead>
<tbody>
<tr>
<td>ROP</td>
</tr>
<tr>
<td>------</td>
</tr>
<tr>
<td>(-) n=13</td>
</tr>
<tr>
<td>(+) n=16</td>
</tr>
<tr>
<td>p</td>
</tr>
</tbody>
</table>

ROP: Retinopathy of prematurity; GA: Gestational age; BW: Birth weight.
number of transfusions, and more infections than the stage 1 ROP group. Despite lack of statistical significance, IGF-1 levels of patients with stage 2 ROP at postconceptional age 32 weeks tended to be lower (13.65 ng/ml vs 45.6 ng/ml) than the stage 1 ROP group with mean values below the 30 ng/ml which is considered to be critical during retinal vascularization.

Considering GA, number of transfusions, infections, duration of oxygen and ventilator treatment were all significantly different in patients with ROP, logistic regression analysis was done which showed that PRBC transfusions were the most effective parameter in our group and after the 3–4th transfusion each PRBC transfusion was associated with 1.61 times increased risk of ROP \( \beta=0.48, p=0.033, OR:1.61 (1.03–2.51) \).

**Discussion**

In this study, we showed that erythrocyte transfusion increases the possibility of ROP in premature infants. However, we have not found any statistically significant difference between pre and post transfusion levels of IGF-1 and IGFBP-3 in babies with and without ROP.

ROP continues to be a challenge for the neonatologists and ophthalmologists taking care of preterm newborns despite technological advances in neonatal intensive care and ROP treatment. Although prematurity and oxygen toxicity are the 2 major reasons of ROP the mechanism is much more complicated. In their elegant research Hellstrom et al. have shown the 2 phases of ROP are completely diverse and require different approach. Phase 1 is a period of arrest of retinal vascularization due to decreased retinal VEGF and systemic IGF-1, whereas phase 2 is a period of neovascularization due to increased IGF-1 and retinal VEGF corresponding to postconceptional 34–35 weeks. If IGF-1 levels were below 30 ng/ml for a long time before this period the risk of proliferative ROP was higher.\(^{[8]}\) Same group of authors have also shown that each 5 µg/l (5 ng/ml) increase in serum IGF-1 levels during 30–33 weeks postconceptional age decreased the risk of proliferative ROP by 45%.\(^{[22]}\) Postnatal head growth deficit among preterm infants have also been found to go parallel to development of ROP and IGF-1 deficit.\(^{[23]}\) Therefore there is little doubt that IGF-1 plays a major role in ROP together with VEGF. Although it is required for retinal vascularization VEGF can not stimulate retinal vascular development without IGF-1, for IGF-1 is necessary for the maximum stimulation of MAPK pathway by

---

**Table 2. Serum IGF-1, IGFBP-3 levels pre and post PRBC transfusions in patients with and without mild ROP**

<table>
<thead>
<tr>
<th>ROP (+) n=16 Mean±SD</th>
<th>ROP (-) n=13 Mean±SD</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>1&lt;sup&gt;st&lt;/sup&gt; Transfusion n=29</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pre Transfusion IGF-1 (ng/ml)</td>
<td>33.59±45.27</td>
<td>31.61±101.5</td>
</tr>
<tr>
<td>Post Transfusion IGF-1 (ng/ml)</td>
<td>61.05±92.18</td>
<td>24.94±42.43</td>
</tr>
<tr>
<td>PCA:32w</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pre trans fusion IGFBP-3 (ng/ml)</td>
<td>1271.46±707.34</td>
<td>914.94±263.9</td>
</tr>
<tr>
<td>Post Transfusion IGFBP-3 (ng/ml)</td>
<td>1312.9±806</td>
<td>1314.09±302.76</td>
</tr>
<tr>
<td>2&lt;sup&gt;nd&lt;/sup&gt; transfusion n=16</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pre Transfusion IGF-1 (ng/ml)</td>
<td>76.25±95.46</td>
<td>–</td>
</tr>
<tr>
<td>Day of life 18</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Post Transfusion IGF-1 (ng/ml)</td>
<td>101.74±132.24</td>
<td>–</td>
</tr>
<tr>
<td>PCA: 33 w</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pre Transfusion IGFBP-3 (ng/ml)</td>
<td>1383.24±850.69</td>
<td>–</td>
</tr>
<tr>
<td>Post Transfusion IGFBP-3 (ng/ml)</td>
<td>1027.24±565.87</td>
<td>–</td>
</tr>
</tbody>
</table>

IGF-1: Insulin growth factor 1; IGFBP-3: Insulin like growth factor binding protein 3; ROP: Retinopathy of prematurity; PRBC: Packed red blood cells; PCA: Post conceptional age.
VEGF which is important for cell proliferation. However the timing of rise in IGF-1 levels is important as summarized above. On the other hand inflammation is a known inhibitor of IGF-1 which might explain the increased incidence of ROP in preterms with sepsis.

IGFBP-3 the major binding protein of IGF-1 has recently been shown to suppress ROP by inhibition of oxygen induced vessel loss. Lofqvist et al. have measured IGFBP-3 levels in preterm newborns and found low IGFBP-3 levels (802 ng/ml) at 30–35 weeks postconceptional age in infants with ROP compared to the ones without ROP (974 ng/ml). Therefore IGFBP-3 together with IGF-1 seems to be important in the prevention of ROP.

The effect of blood transfusions on ROP has been studied even longer than the effect of mediators with the research revealing conflicting results. Hesse et al. have found increased risk of ROP with blood transfusions but have not been able to relate this finding to increased iron load. However Dani et al. have shown that PRBCs might contain significant amount of iron (0.48 mg/ml) which could increase free iron in the preterm newborn. Free iron might catalyze fenton reactions producing free hydroxyl radicals and injure retinal cells. Hirano et al. have supported the same mechanism by showing increased free iron after blood transfusion.

Perhaps the most interesting possible explanation for the effect of PRBC transfusions on ROP has come from Hubler et al. measuring IGF-1 levels in the transfused PRBCs. They have found that the IGF-1 in RBC transfusions corresponds to a single dose of 1µg/kg IGF-1 treatment which the authors suggest might lead to increased VEGF induced retinal neovascularization if given at the critical period for proliferative ROP.

In our study we have not found any statistically significant difference between pre and post transfusion levels of IGF-1 and IGFBP-3 in babies with and without ROP. Since proliferative ROP was observed in only 1 patient, the statistical analyses were done excluding that patient comparing patients without ROP and patients with mild ROP (stage 1, 2). As expected patients with mild ROP had lower GA, longer duration of oxygen and ventilation treatment, more episodes of infection and more number of PRBC transfusions compared to the non-ROP group. However we did not observe any difference of IGF-1, IGFBP-3 levels between the 2 groups at the time corresponding to 32 postconceptional age. This finding might be due to lack of proliferative ROP in the compared group since in other studies investigating the role of these mediators focus has mostly been on proliferative ROP. However IGF-1 levels tended to be lower (13.65 ng/ml <30 ng/ml) in our patients with stage 2 ROP at postconceptional 32 weeks although the difference did not reach significance, which could be due to the small number of patients.

PRBC transfusions were found to be a major factor for development of mild ROP in our study in addition to GA and oxygen. After the 3–4th PRBC transfusion each new transfusion increased the risk of mild ROP by 1.61 times. This finding might suggest that together with well controlled oxygen therapy, well controlled transfusion strategies are also important in the prevention of mild ROP. Considering that although mostly regresses spontaneously mild ROP is still an important morbidity making the patient prone to other retinal problems in late childhood or adulthood, this effort is well worth to try.

The most important limitation of our study is the low numbers of ROP in the bigger stage (stage 2 and over).

Conclusion

Our results suggest that; PRBC transfusions play an important role in the development of mild ROP. Therefore, controlled erythrocyte transfusion in the neonatal period will help prevent ROP development. However, in order to investigate the role of RBC transfusion on IGF-1 and IGFBP-3, which needs studies further stage large series of ROP.

Acknowledgment: This study was supported by Gazi University Hospital, Department of Pediatrics, Division of Newborn Medicine.

Conflict of interest: There are no relevant conflicts of interest to disclose.

References

11. Smith LE. Pathogenesis of retinopathy of prematurity. Semin Peri-


